Search hospitals > Massachusetts > Boston
Ophthalmic Consultants of Boston
Claim this profileBoston, Massachusetts 02114
Global Leader in Age-Related Macular Degeneration
Global Leader in Macular Edema
Conducts research for Swelling
Conducts research for Diabetic Macular Edema
Conducts research for Atrophy
108 reported clinical trials
5 medical researchers
Summary
Ophthalmic Consultants of Boston is a medical facility located in Boston, Massachusetts. This center is recognized for care of Age-Related Macular Degeneration, Macular Edema, Swelling, Diabetic Macular Edema, Atrophy and other specialties. Ophthalmic Consultants of Boston is involved with conducting 108 clinical trials across 60 conditions. There are 5 research doctors associated with this hospital, such as Jeffrey S Heier, MD, Chirag Shah, MD, Lana M Rifkin, MD, and Girag Shah, MD.Area of expertise
1Age-Related Macular Degeneration
Global LeaderStage IV
ABCA4 positive
2Macular Edema
Global LeaderTop PIs
Jeffrey S Heier, MDOphthalmic Consultants of Boston1 year of reported clinical research
Studies Age-Related Macular Degeneration
Studies Macular Edema
7 reported clinical trials
8 drugs studied
Chirag Shah, MDCleveland Clinic, Case Comprehensive Cancer Center1 year of reported clinical research
Studies Breast Cancer
Studies Ductal Carcinoma
7 reported clinical trials
11 drugs studied
Lana M Rifkin, MDOphthalmic Consultants of Boston4 years of reported clinical research
Studies Uveitis
Studies Swelling
2 reported clinical trials
5 drugs studied
Girag Shah, MDOphthalmic Consultants of Boston1 year of reported clinical research
Studies Age-Related Macular Degeneration
Studies Atrophy
1 reported clinical trial
2 drugs studied
Clinical Trials running at Ophthalmic Consultants of Boston
Age-Related Macular Degeneration
Atrophy
Retinitis Pigmentosa
Diabetic Retinopathy
Retinitis
Graves' Ophthalmopathy
Graves' Eye Disease
Thyroid Disease
Eye Diseases
Choroidal Detachment
PDS Implant with Ranibizumab
for Age-Related Macular Degeneration
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
Recruiting2 awards Phase 33 criteria
SKG0106
for Age-Related Macular Degeneration
This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.
Recruiting1 award Phase 1 & 2
Stem Cell Therapy
for Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of the eye. There are 2 types of AMD - wet AMD and dry AMD. The advanced stage of dry AMD causes vision loss. This is known as geographic atrophy. AMD makes everyday tasks like reading or driving difficult. ASP7317 is a potential new treatment for people with AMD. ASP7317 are human stem cells which have changed into cells found in the retina. ASP7317 is injected under the macula. It is hoped that ASP7317 will replace some of the damaged cells in the macula and improve vision for people with dry AMD. Before ASP7317 is available as a treatment, the researchers need to check its safety and how well it is tolerated. They will also check for signs of improved vision. People taking part in this study will be older people who have geographic atrophy caused by dry AMD. This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP7317. There will be 3 doses of ASP7317. These are low, medium and high numbers of cells. ASP7317 will be injected under the macula after the person is given either a local or a general anesthetic. To prevent the body from rejecting the cells, people will take tablets of tacrolimus a few days before receiving ASP7317 for up to a few weeks afterwards. Other medicines will be taken during this time to stop infections. There will be 2 groups in the study. Group 1 will be people with severe vision loss and Group 2 will be people with moderate vision loss. There will be different small groups of people within Group 1 and Group 2, with each small group receiving 1 of the 3 doses of ASP7317. Different small groups of people within Group 1 and Group 2 will receive lower to higher doses of ASP7317. Each small group will only receive 1 dose. Group 1 will start treatment first. At each dose, a medical expert panel will check the results of the first person in the group to decide if the rest of the group will receive the same dose. Then, the panel will decide if more people may receive the same dose or if the next group may receive the next highest dose. The panel will use the results from the lower dose of Group 1 to decide when Group 2 starts treatment (also at the lower dose). The panel will also use the results of the middle and higher doses in Group 1 to decide when and how many people in Group 2 can receive these doses. During the study, people will visit the clinic several times for up to 12 months (1 year). During all visits, the study doctors will check for any medical problems after receiving ASP7317. Vital signs will be checked a few days before treatment with ASP7317 and up to about a month afterwards. Vital signs include blood pressure, pulse, and temperature. At some visits, the study doctors will also take blood samples for blood tests. At most visits, people will have eye tests and have different images, scans, and measurements taken. This could be for the affected eye or both eyes, depending on the test. People can visit the clinic extra times, if needed.
Recruiting1 award Phase 110 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Ophthalmic Consultants of Boston?
Ophthalmic Consultants of Boston is a medical facility located in Boston, Massachusetts. This center is recognized for care of Age-Related Macular Degeneration, Macular Edema, Swelling, Diabetic Macular Edema, Atrophy and other specialties. Ophthalmic Consultants of Boston is involved with conducting 108 clinical trials across 60 conditions. There are 5 research doctors associated with this hospital, such as Jeffrey S Heier, MD, Chirag Shah, MD, Lana M Rifkin, MD, and Girag Shah, MD.